Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574197 · ClinicalTrials.gov registry record · Phase 4
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
A Phase 4 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT00574197 is a Phase 4 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00574197, a Phase 4 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-coated, Myfortic® is presently FDA approved for the prevention of acute kidney rejection only. There is no clinical data of its use in heart transplant patients.
Interventions
- DRUG Mycophenolate Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574197
The ClinicalTrials.gov registry entry for NCT00574197 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mycophenolate Sodium is the first listed.
NCT00574197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574197 about?
NCT00574197 is a clinical study titled "Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients". Mycophenolate sodium (Myfortic®) is a newly developed enteric-coated tablet version of mycophenolate mofetil (Cellcept®) which is currently used as therapy for the prevention of transplant rejection. Myfortic® was developed to improve the gastrointestinal tolerability of Cellcept®. The new enteric-c...
What is the current status of trial NCT00574197?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2006-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00574197?
The interventions under investigation include: Mycophenolate Sodium (DRUG).
Who is sponsoring clinical trial NCT00574197?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.